The agreement hands Biogen as much as $250 million in exchange for milestone payments and sales royalties for litifilimab, which is in a pair of late-stage studies in lupus.

Biogen posted strong Q4 results, surpassing estimates, while forecasting a 2025 revenue decline. The company secured up to ...

The Hyderabad centre will focus on accelerating the delivery of Enfabrica’s cutting-edge SuperNIC silicon and networking ...

South Africa’s research and development funding, human resource development and infrastructure agency, the National Research Foundation (NRF), and the FirstRand Empowerment Foundation (FREF), have ...

We are excited to collaborate with Biogen on litifilimab,” said Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer. “Royalty Pharma offers tailored, win-win funding solutions for ...

Coordinator General of COMSTECH, Prof. Dr. Iqbal Choudhry Wednesday emphasized that scientific research and technological ...

The IFR analyzes how robotics R&D strategies differ between China, Japan, Korea, the European Union, and the U.S.